Introduction {#s1}
============

Cancer arises as a result of complex interactions between genetic and environmental factors and has become a major public health problem all over the world [@pone.0088748-Bredberg1]--[@pone.0088748-Siegel1]. In recent years, many individual studies have set out to determine whether there is an association between genetic polymorphisms and cancer susceptibility, such as *Fas* -1377 G/A polymorphism and cancer susceptibility. However, these studies showed conflicting results that failed to provide compelling evidence for cancer susceptibility [@pone.0088748-Sibley1]--[@pone.0088748-Gormus1].

Apoptosis is a process of programmed cell death regulated by genes. Inappropriate regulation of apoptosis could lead to a broad range of human disorders including cancer [@pone.0088748-Thompson1]--[@pone.0088748-Hajra1]. *Fas* is a member of the tumor necrosis factor receptor superfamily and regulates apoptotic activities in activated lymphocytes [@pone.0088748-Li1]. Located on chromosome 10q24.1, *Fas* is highly polymorphic [@pone.0088748-Inazawa1]. A functional polymorphism with a G to A substitution at -1377 position within the *Fas* gene has been extensively explored in the field of cancer. But there is no decisive conclusion of the role of this polymorphism in cancer development [@pone.0088748-Sibley1], [@pone.0088748-Kim1]. In addition, several studies have been subsequently published since a previous meta-analysis was reported in 2009 [@pone.0088748-Qiu1]. In view of this, we decided to carry out a meta-analysis including 27 eligible studies published to date to systematically and comprehensively estimate the association between *Fas* -1377 G/A polymorphism and susceptibility to cancer.

Materials and Methods {#s2}
=====================

Literature Search Strategy {#s2a}
--------------------------

The databases of PubMed, Embase, and Web of Science were searched (the last search was updated in May 2013) to identify all relevant publications on the association between *Fas* -1377 G/A polymorphism and cancer risk. The following search terms and their synonyms were used: "*Fas*", "1377 G/A" or "CD95" or "rs2234767", "polymorphism" or "variation", and "cancer". We also manually searched the reference lists of all eligible studies and review articles to obtain additional usable data that can be included in the current meta-analysis.

Inclusion Criteria and Exclusion Criteria {#s2b}
-----------------------------------------

We selected eligible studies according to the following criteria: (1) the study must have a case-control design; (2) the association between *Fas* -1377 G/A polymorphisms and cancer risk must be examined; (3) adequate genotyping data must be contained such that odds ratios (ORs) with 95% confidence intervals (CIs) could be calculated; (4) the study had to be published in English and use human subjects. Exclusion criteria were: (1) insufficient information on the distribution of *Fas* -1377 genotypes; (2) case-only studies; (3) duplicated publications. If a study was subsequently updated, we selected the study with the largest sample size. Two investigators independently reviewed all studies to examine whether they fulfilled the inclusion criteria.

Data Extraction {#s2c}
---------------

Two independent investigators (Peiliang Geng and Jianjun Li) extracted the original data according to the inclusion criteria and exclusion criteria to ensure the accuracy of the retrieved information. The data extracted from each eligible study included the first author\'s name, year of publication, cancer type, ethnicity, source of controls, method adopted for genotyping, number of cases and controls and genotype frequencies. Disputes were settled by consulting the third person (Houjie Liang).

Statistical Analysis {#s2d}
--------------------

Crude ORs with 95% CIs were calculated to evaluate the strength of the association between *Fas* -1377 G/A polymorphism and cancer risk. The pooled ORs were performed for additive model, dominant model and recessive model. Subgroup analysis by cancer type, ethnicity and source of control were also conducted to further assess if the *Fas* -1377 polymorphism was associated with cancer susceptibility in each subgroup. Heterogeneity assumption was evaluated by the chi-square based Q-test and I^2^ statistics [@pone.0088748-Higgins1], [@pone.0088748-Higgins2], *P*\>0.05 for the Q test or I^2^\<50% suggested a lack of heterogeneity. In this situation, the OR of each study was calculated by the fixed-effects model (the Mantel-Haenszel method) [@pone.0088748-Mantel1]. If *P*\<0.05 or I^2^\>50%, the random-effects model (the DerSimonian and Laird method) was used [@pone.0088748-DerSimonian1]. Sensitivity analysis was performed by removing one study at a time to ensure that our findings were not driven by any single study. The evaluation of potential publication bias was performed using the Begg\'s funnel plots and Egger\'s test [@pone.0088748-Egger1]. Hardy-Weinberg equilibrium (HWE) of the control groups was tested by the χ^2^ test for goodness of fitness. All statistical analyses were performed by STATA version 12.0 (Stata Corporation, College Station, TX, USA). A level of *P*\<0.05 was accepted as statistically significant.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

We initially identified 147 potentially relevant studies, of which 27 met the pre-described inclusion criteria and were included in the meta-analysis of the association between Fas -1377G/A polymorphism and cancer risk ([Figure 1](#pone-0088748-g001){ref-type="fig"}). Characteristics of all eligible case-control studies for the relationship of *Fas* -1377G/A polymorphism with cancer risk are summarized in [Table 1](#pone-0088748-t001){ref-type="table"}. Of the twenty-seven studies included, an array of cancers including AML [@pone.0088748-Sibley1], [@pone.0088748-Kim1], breast cancer [@pone.0088748-Crew1]--[@pone.0088748-Hashemi1], cervical cancer [@pone.0088748-Kang1]--[@pone.0088748-Sun1], lung cancer [@pone.0088748-Park1], [@pone.0088748-Gormus1], [@pone.0088748-TerMinassian1], [@pone.0088748-Zhang2], gastric cancer [@pone.0088748-Zhou1], [@pone.0088748-Kupcinskas1], melanoma [@pone.0088748-Li2], [@pone.0088748-Zhang3], oral cancer [@pone.0088748-Wang2], [@pone.0088748-Karimi1], and several other cancers [@pone.0088748-Krippl1]--[@pone.0088748-Cao1] were involved. The subgroup analysis was carried out by cancer type, ethnicity and source of control, respectively. Genotype frequencies were available in all of the 27 studies.

![Flow diagram of study identification.](pone.0088748.g001){#pone-0088748-g001}

10.1371/journal.pone.0088748.t001

###### Main characteristics of the 27 eligible studies.

![](pone.0088748.t001){#pone-0088748-t001-1}

  Authors        Year   Source of control   Ethnicity    Cancer type     Genotyping method   Case   Control   HWE                                                            
  ------------- ------ ------------------- ----------- ---------------- ------------------- ------ --------- ----- ----- ------ ----- ------ ------ ----- ----- ------ ----- --------
  Sibley         2003      Population       European         AML             PCR--RFLP       471      319     136   16    774    168   931    726    186   19    1638   224   0.087
  Sun            2004      Population         Asian       Esophageal         PCR--RFLP       588      250     234   104   734    442   648    273    306   69    852    444   0.218
  Kripple        2004      Population       European        Breast            TaqMan         499      371     120    8    862    136   497    401    92     4    894    100   0.610
  Lai            2005       Hospital          Asian        Cervical           TaqMan         318      127     138   53    392    244   318     99    165   54    3633   273   0.293
  Sun            2005      Population         Asian        Cervical          PCR--RFLP       314      144     144   26    432    196   615    282    277   56    841    389   0.304
  Zhang          2005      Population         Asian          Lung            PCR--RFLP       1000     413     433   154   1259   741   1270   539    601   130   1679   861   0.046
  Li             2006       Hospital          Asian        Bladder           PCR--RFLP       216      66      104   46    236    196   252     81    124   47    286    218   0.970
  Park           2006       Hospital          Asian          Lung            PCR--RFLP       582      187     300   95    674    490   582    172    313   97    657    507   0.024
  Li             2006       Hospital        European       Melanoma          PCR--RFLP       602      486     107    9    1079   125   603    459    134   10    1052   154   0.951
  Zhang          2006       Hospital        European        SCCHN            PCR--RFLP       721      562     142   17    1266   176   1234   957    264   13    2178   290   0.268
  Gormas         2007      Population       European         Lung               PCR           94      21      73     0    115    73     50     13    37     0     63    37    \>0.05
  Zhang          2007      Population         Asian         Breast           PCR--RFLP       840      293     418   129   1004   676   839    345    382   112   1072   606   0.700
  Crew           2007      Population       European        Breast            TaqMan         1057     809     225   23    1843   271   1106   847    234   25    1928   284   0.069
  Koshkina       2007       Hospital        European     Osteosarcoma        PCR--RFLP       123      99      22     2    220    26    510    400    100   10    900    120   0.210
  Zhang          2007      Population       European       Melanoma          PCR--RFLP       229      183     41     5    407    51    351    269    70    12    608    94    0.009
  Ter-Minassi    2008       Hospital        European         Lung             TaqMan         2174    1645     492   37    3782   566   1497   1138   336   23    2612   382   0.751
  Kang           2008      Population         Asian        Cervical          PCR--RFLP       154      54      69    31    177    131   168     56    82    20    194    142   0.998
  Yang           2008      Population         Asian       Pancreatic         PCR--RFLP       397      186     169   42    541    253   907    420    376   111   1216   598   0.062
  Zhou           2009      Population         Asian        Gastric           PCR--RFLP       262      124     117   21    365    159   524    225    251   48    701    347   0.062
  Cao            2010      Population         Asian     Nasopharyngeal       PCR--RFLP       576      141     264   171   546    606   608    172    303   133   647    569   0.984
  Kim            2010      Population         Asian          AML                PCR          592      195     303   94    693    491   858    286    427   145   999    717   0.501
  Wang           2010      Population         Asian          Oral            PCR--RFLP       431      146     208   77    500    362   333    115    165   53    395    271   0.628
  Zhu            2010       Hospital          Asian         Renal            PCR--RFLP       353      124     173   56    421    285   365    161    161   43    483    247   0.777
  Kupcinskas     2011       Hospital        European       Gastric            TaqMan         114      95      18     1    208    20    238    197    40     1    434    42    0.492
  Wang           2012       Hospital          Asian         Breast           PCR--RFLP       375      138     171   66    447    303   496    197    246   53    640    352   0.064
  Hashemi        2013      Population         Asian         Breast              PCR          134      20      106    8    146    122   152     26    115   11    167    137   \>0.05
  Karimi         2013      Population         Asian          Oral            PCR--RFLP       139      88      42     9    218    60    126     84    30    12    198    54    0.001

PCR: polymerase chain reaction; PCR-RFLP: PCR-restriction fragment length polymorphism; TaqMan: TaqManSNP; AML: acute myeloid leukemia; SCCHN: squamous cell carcinoma of the head and neck; HWE: Hardy-Weinberg equilibrium.

Meta-analysis {#s3b}
-------------

Major results of the meta-analysis are presented in [Table 2](#pone-0088748-t002){ref-type="table"}. No significant between-study heterogeneity was detected across studies and thus we selected the fix-effects model to summarize the ORs. Overall, we found a significant association between *Fas* -1377G/A polymorphism and cancer risk under the additive model (OR, 1.16, 95%CI = 1.06--1.27, *P* ~heterogeneity~  = 0.381), but the association was more pronounced under the recessive model (OR, 1.19, 95%CI = 1.10--1.29, *P* ~heterogeneity~  = 0.137) ([Figure 2](#pone-0088748-g002){ref-type="fig"}, [3](#pone-0088748-g003){ref-type="fig"}). In the subgroup analysis by cancer type, significantly increased risk was observed in breast cancer (additive model: OR, 1.24, 95%CI = 1.04--1.58, *P* ~heterogeneity~  = 0.614; recessive model: OR, 1.24, 95%CI = 1.02--1.51, *P* ~heterogeneity~  = 0.349) and lung cancer (recessive model: OR, 1.25, 95%CI = 1.04--1.49, *P* ~heterogeneity~  = 0.090).

![Meta-analysis for the association between Fas -1377 G/A polymorphism and cancer risk by fixed-effects model (additive model; stratified by ethnicity).](pone.0088748.g002){#pone-0088748-g002}
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###### Main results of the pooled data in the meta-analysis.

![](pone.0088748.t002){#pone-0088748-t002-2}

                                               Additive model       Dominant model   Recessive model                                                                     
  ---------------------------------------- ----------------------- ---------------- ----------------- ------------------- ------- ------ ----------------------- ------- ------
  Cancer type                                                                                                                                                            
  AML                                         1.07 (0.82, 1.14)         0.080             67.4         1.14 (0.99, 1.30)   0.011   84.6     1.02 (0.79, 1.32)     0.125   57.6
  Breast                                    **1.28 (1.04, 1.58**)       0.614               0          1.08 (0.99, 1.19)   0.602    0     **1.24 (1.02, 1.51)**   0.349   10.0
  Cervical                                    0.96 (0.72, 1.29)         0.432               0          0.96 (0.83, 1.12)   0.590    0       1.08 (0.82, 1.42)     0.245   28.9
  Lung                                        1.19 (0.98, 1.43)         0.163             45.0         1.01 (0.92, 1.10)   0.960    0     **1.25 (1.04, 1.49)**   0.090   58.4
  Melanoma                                    0.74 (0.37, 1.47)         0.659               0          0.82 (0.66, 1.03)   0.795    0       0.77 (0.39, 1.53)     0.627    0
  Gastric                                     0.85 (0.50, 1.46)         0.526               0          0.93 (0.74, 1.17)   0.885    0       0.90 (0.53, 1.52)     0.547    0
  Oral                                        1.03 (0.71, 1.48)         0.444               0          1.03 (0.84, 1.26)   0.749    0       1.04 (0.74, 1.47)     0.313   1.9
  Other                                       1.26 (1.08, 1.47)         0.301             16.9         1.02 (0.94, 1.11)   0.940    0       1.31 (1.13, 1.52)     0.139   38.0
  Ethnicity                                                                                                                                                              
  European                                    1.23 (0.94, 1.60)         0.419              1.8         1.04 (0.96, 1.13)   0.069   43.4     1.22 (0.93, 1.58)     0.519    0
  Asian                                     **1.15 (1.05, 1.26)**       0.318             11.6         1.02 (0.97, 1.07)   0.994    0     **1.19 (1.09, 1.30)**   0.060   37.4
  Source of control                                                                                                                                                      
  Population                                **1.16 (1.05, 1.29)**       0.383              6.1         1.05 (0.99, 1.10)   0.587    0     **1.19 (1.08, 1.32)**   0.073   36.4
  Hospital                                    1.15 (0.97, 1.35)         0.311             14.3         0.99 (0.92, 1.06)   0.783    0     **1.19 (1.02, 1.39)**   0.419   2.2
  Total                                     **1.16 (1.06, 1.27)**       0.381              5.7         1.02 (0.98, 1.07)   0.722    0     **1.19 (1.10, 1.29)**   0.137   23.7
  Total[\*](#nt103){ref-type="table-fn"}      1.16 (1.05, 1.28)         0.484               0          1.03 (0.98, 1.08)   0.583    0       1.19 (1.08, 1.30)     0.249   15.8

AML: acute myeloid leukemia; P~h~: p-value of heterogeneity test; CI: confidence interval; OR: odds ratio;

^\*^meta-analysis results after removing the studies deviating from Hardy-Weinberg equilibrium (HWE).

![Meta-analysis for the association between Fas -1377 G/A polymorphism and cancer risk by fixed-effects model (recessive model; stratified by ethnicity).](pone.0088748.g003){#pone-0088748-g003}

Subgroup analysis by ethnicity also provided evidence for an association in Asian populations (additive model: OR, 1.15, 95%CI = 1.05--1.26, *P* ~heterogeneity~  = 0.318; recessive model: OR, 1.19, 95%CI = 1.09--1.30, *P* ~heterogeneity~  = 0.060), but not in European populations. In the succeeding analysis by source of control, an elevated cancer risk was observed in both population-based and hospital-based studies ([Table 2](#pone-0088748-t002){ref-type="table"}).

Sensitivity Analysis {#s3c}
--------------------

We performed a leave-one-out sensitivity analysis by omitting one study at a time to assess the stability of the combined results. The results suggested that our findings were not substantially affected by any single study (data not shown).

Publication Bias {#s3d}
----------------

Begg\'s funnel plot and Egger\'s test were performed to detect publication bias. No statistically significant evidence of publication bias was revealed (Begg\'s test: *P* = 0.826; Egger\'s test: *P* = 0.721, additive model) ([Figure 4](#pone-0088748-g004){ref-type="fig"}).

![Publication bias test for all included studies (additive model).](pone.0088748.g004){#pone-0088748-g004}

Discussion {#s4}
==========

The human *Fas* gene mapped on chromosome 10q24.1 consists of nine exons and eight introns [@pone.0088748-Inazawa1]. -1377 G/A polymorphism, located in the promoter region of the *Fas* gene, has been investigated in a variety of previous studies looking at cancer risk [@pone.0088748-Park1], [@pone.0088748-Crew1], [@pone.0088748-Koshkina1], [@pone.0088748-Kang1]. However, these findings remain controversial rather than conclusive. This might be attributed to the different ethnicities, distinct study design, and sample inadequacy in each of the published studies. But meta-analysis could avoid the shortcomings and convincingly estimate the genetic association through including all relevant studies.

In our meta-analysis, we observed *Fas* -1377G/A polymorphism was overall associated with cancer susceptibility under the additive model and the recessive model. Several published meta-analyses observed the same finding that *Fas* -1377 G/A polymorphism was associated with cancer risk as well as some common diseases, such as autoimmune rheumatic diseases, systemic lupus erythematosus [@pone.0088748-Lu1]--[@pone.0088748-Qiu1]. The detection power of the four meta-analyses, however, may be limited largely because of sample insufficiency: 4 publications (996 cases and 1,160 controls) were included by Lu et al. [@pone.0088748-Lu1], 5 (615 cases and 622 controls) by Lee et al. [@pone.0088748-Lee1], 3 (444 cases and 442 controls) by Xiang et al. [@pone.0088748-Xiang1] and 17 (10,564 cases and 12,075 controls) by Qiu et al [@pone.0088748-Qiu1]. Our meta-analysis nevertheless summarized data from 27 studies composed of 13,355 cases and 16,078 controls. It should be noted that study size is obviously important to know the proportion of false positive findings of meta-analysis. Therefore, the relatively larger sample may assure the statistical power of our study. Deviation from HWE was observed in several studies, which may result from misclassification of genotypes, because multiple genotyping methods were used across studies. When we reanalyzed the studies without departure form HWE, the general results were not significantly altered, suggesting our findings are robust and convincing.

Apart from the comparison among all subjects, we also performed stratification analysis by cancer type. We found that *Fas* -1377 G/A polymorphism increased the risk of some cancers, such as breast cancer and lung cancer. Our findings were consistent with those revealed in the previous studies [@pone.0088748-Sibley1], [@pone.0088748-Gormus1], [@pone.0088748-Crew1], [@pone.0088748-Kang1], but contradictory discoveries that there was no association between *Fas* -1377 G/A polymorphism and lung cancer were also suggested in two studies [@pone.0088748-Kim1], [@pone.0088748-Park1]. The underlying etiology mechanisms differ substantially across cancers, and the role of *Fas* -1377 G/A polymorphism in various caners requires to be identified by future larger studies.

In addition, in the subgroup analysis by ethnicity, *Fas* -1377 G/A polymorphism was found to increase cancer risk in Asian populations under several genetic models, such as the recessive model and the additive model. However, this association was obtained in European populations. There is obvious disparity in genotype frequencies between the two ethnic groups (GA: 21.3% vs 47.7%; AA: 1.5% vs 13.2%). It is known that different genetic background donates a series of differences between ethnic groups, for instance, frequency of exposure to cancer-causing agents and diverse lifestyles, which are important components in the process of cancer progression.

In the final subgroup analysis by control source, we observed significant association in both population-based and hospital-based studies. However, investigators demonstrated a different discovery of significantly increased cancer risk associated with *Fas* -1377 AA genotype among studies based on population-based controls, but not among studies of hospital-based controls [@pone.0088748-Qiu1]. Control subjects in some hospital-based studies may be poorly-defined reference populations and failed to well represent the general population, leading to some biases in the analysis, but the relatively small sample may be responsible for a large part of the inconsistency.

Some limitations in our meta-analysis need to be addressed. To begin with, in the subgroup analysis by cancer type, significant association was not observed in several cancers, such as gastric cancer, melanoma cancer and oral cancer. *Fas* -1377 G/A polymorphism and these cancers may be positively correlated, which may be masked due to the small sample size in this study. Furthermore, there existed heterogeneity between studies. The reason might be attributable to the different genetic backgrounds of the subjects and study design in each of the included studies. Finally, this meta-analysis was carried out among Asian and European populations, thus the results can not be applicable in other ethnicities.

In summary, the meta-analysis provided evidence that *Fas* -1377 G/A polymorphism might be associated with an increased cancer risk. Significant association was also found in subgroup analyses by cancer type, ethnicity and source of control. In future, studies with a larger sample size and multiple ethnic groups are required to further validate the relationship between *Fas* -1377 G/A polymorphism and cancer susceptibility.
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